Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
Because interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectional study was carried out, comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (noninterruption group, NIG). Interruption was defined as the discontinuation of highly active antiretroviral therapy (HAART) for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. A total of 83 subjects participated in the study (IG: n = 27; NIG: n = 56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [P = .003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [P = 0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. In this study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
Muñoz-Moreno
Jose A
JA
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain. jmunoz@flsida.org
Fumaz
Carmina R
CR
Prats
Anna
A
Ferrer
Maria J
MJ
Negredo
Eugènia
E
Pérez-Alvarez
Núria
N
Moltó
José
J
Gómez
Guadalupe
G
Garolera
Maite
M
Clotet
Bonaventura
B
D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology*; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D015995:Prevalence; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000453:epidemiology; D013375:Substance Withdrawal Syndrome; D016312:Treatment Refusal
D044966:Anti-Retroviral Agents
J Neurovirol. 2005 Jul;11(3):265-73
16036806
AIDS. 2001 Jun 15;15(9):F29-40
11416735
AIDS. 2008 Aug 20;22(13):1583-8
18670217
N Engl J Med. 2006 Nov 30;355(22):2283-96
17135583
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1301-7
18844464
J Neurovirol. 2004 Dec;10(6):350-7
15765806
AIDS. 2004 Jan 1;18 Suppl 1:S11-8
15075493
J Neurovirol. 2004 Aug;10(4):223-32
15371152
AIDS. 2009 Apr 27;23(7):757-9
19307943
AIDS. 1999 May 28;13(8):F59-62
10371167
J Neurovirol. 2008 Nov;14(6):550-7
19016380
J Infect Dis. 2002 Sep 15;186(6):851-4
12198623
Viral Immunol. 2005;18(3):579-81
16212537
Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S38-44
16265612
Neurology. 2006 May 9;66(9):1447-50
16682686
Assessment. 1999 Jun;6(2):147-78
10335019
J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82
17356465
Neurology. 2007 Oct 30;69(18):1789-99
17914061
AIDS. 2002 May 3;16(7):1083-4
11953480
J Infect Dis. 2003 Jun 1;187(11):1818-21
12751041
Ann Neurol. 1997 Nov;42(5):679-88
9392566
J Med Virol. 2009 Mar;81(3):481-7
19152399
J Neurovirol. 2004;10 Suppl 1:44-51
14982739
AIDS. 2007 Jan 11;21(2):169-78
17197807
N Engl J Med. 2001 Feb 15;344(7):472-80
11172188
J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63
19731418
Brain. 2006 Feb;129(Pt 2):503-16
16317019
J Neurovirol. 2002 Apr;8(2):136-42
11935465
Neurology. 2000 Feb 22;54(4):921-6
10690987
J Neurovirol. 2007 Jun;13(3):225-32
17613712
J Infect Dis. 2005 Mar 15;191(6):890-8
15717264
AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8
15650419
Lancet. 2006 Jun 17;367(9527):1981-9
16782488
AIDS Res Hum Retroviruses. 2005 Aug;21(8):706-13
16131310
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
10611346
AIDS. 2009 Apr 27;23(7):799-807
19114869
AIDS. 2004 Feb 20;18(3):439-46
15090796
AIDS. 2009 Jun 19;23(10):1187-95
19455015
Arch Neurol. 2002 Jun;59(6):923-8
12056927
J Clin Invest. 2005 Feb;115(2):443-50
15668739
AIDS Res Hum Retroviruses. 1999 Jun 10;15(9):811-20
10381169
Clin Infect Dis. 2005 Feb 15;40(4):594-600
15712083
Arch Neurol. 2008 Jan;65(1):65-70
18195140
Ann Neurol. 2004 Sep;56(3):416-23
15349869
AIDS Rev. 2008 Oct-Dec;10(4):236-44
19092979
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52
12370434
Neurology. 2006 Jun 13;66(11):1688-95
16769942